Table 2.

Univariate Cox Models, predictors for freedom from renal replacement therapy

	Hazard Ratio	Lower 95% CI	Upper 95% CI	P
Change, eGFR from pre-intervention to intervention*	1.01	0.98	1.05	0.47
Change, eGFR from intervention-post-intervention**	0.96	0.92	0.99	0.02
eGFR post-intervention †	0.87	0.83	0.91	<0.001
CKD stage
1/2/3A	1.00
3B	1.29	0.37	4.47	0.69
4	4.32	1.35	13.80	0.01
5	13.58	2.46	75.13	0.003
Proteinuria, per 100 mg	1.09	1.06	1.12	<0.001
Bilateral intervention	2.60	1.12	6.07	0.03
ACEI/ARB	1.50	0.35	6.41	0.59
Clopidogrel	1.75	0.71	4.31	0.23
Diabetes	2.55	1.11	5.84	0.03
Coronary artery disease	2.85	0.96	8.42	0.06
Stroke	0.66	0.20	2.21	0.50

^*Per 1 ml/min/1.73m² eGFR trajectory increase for 6–12 months leading up to renal artery stent placement.

^**Per 1 ml/min/1.73m² eGFR trajectory increase from renal artery stent placement up to 6–12 months follow-up.

^†eGFR trajectory from renal artery stent placement up to 6–12 months follow-up among patients with eGFR <40. Among patients with an eGFR at post-intervention <40 ml/min/1.73m², the hazard ratio is for a one unit increase in eGFR, up to 40 ml/min/1.73m².

CKD=chronic kidney disease; ACEI=angiotensin-converting-enzyme inhibitor; ARB=angiotensin receptor blocker; CI=confidence interval Impact of renal function trajectory on dialysis and mortality risk after renal artery revascularization1